Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

74 citing papers in PubMed.

1. Epstein-Barr Virus and Multiple Sclerosis: Mechanistic Insights into Virus-Driven Autoimmunity.Microorganisms · 2026
   Review
2. Why Is MS a More Frequent Complication of EBV Infection in Females?Immunological reviews · 2026
   Review
3. B-cell abundance in perivascular cuffs associates with local lesion activity in multiple sclerosis.Acta neuropathologica communications · 2026
   Article
4. Tertiary Lymphoid Structures in Central Nervous System Disorders.Methods in molecular biology (Clifton, N.J.) · 2025
   Review
5. The Functional Interaction Between Epstein-Barr Virus and MYC in the Pathogenesis of Burkitt Lymphoma.Cancers · 2024
   Review
6. CXCL13 as a Biomarker: Background and Utility in Multiple Sclerosis.Biomolecules · 2024
   Review
7. New views on the complex interplay between degeneration and autoimmunity in multiple sclerosis.Frontiers in cellular neuroscience · 2024
   Article
8. Astrocyte Activation and Drug Target in Pathophysiology of Multiple Sclerosis.Methods in molecular biology (Clifton, N.J.) · 2024
   Review
9. EBV-specific T-cell immunity: relevance for multiple sclerosis.Frontiers in immunology · 2024
   Review
10. EBV and multiple sclerosis: expression of LMP2A in MS patients.Frontiers in neuroscience · 2024
    Article
11. Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis.Nature reviews. Neurology · 2023
    Review
12. Markers of Epstein-Barr Virus Infection in Patients with Multiple Sclerosis.Microorganisms · 2023
    Review
13. Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications.Nature reviews. Neurology · 2023
    Review
14. Progress in etiological diagnosis of viral meningitis.Frontiers in neurology · 2023
    Review
15. Risk factors for multiple sclerosis in the context of Epstein-Barr virus infection.Frontiers in immunology · 2023
    Review
16. Treatment Options for Epstein-Barr Virus-Related Disorders of the Central Nervous System.Infection and drug resistance · 2023
    Review
17. Potential biological contributers to the sex difference in multiple sclerosis progression.Frontiers in immunology · 2023
    Article
18. From bedside to bench: how existing therapies inform the relationship between Epstein-Barr virus and multiple sclerosis.Clinical & translational immunology · 2023
    Review
19. Epstein-Barr virus and multiple sclerosis: moving from questions of association to questions of mechanism.Clinical & translational immunology · 2023
    Review
20. A Review of Compartmentalised Inflammation and Tertiary Lymphoid Structures in the Pathophysiology of Multiple Sclerosis.Biomedicines · 2022
    Review

14 more citing papers are in PubMed but not listed here.

Corrections and comments

• Comment on
  Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.2009

Authors and funding

16 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as